FNX-006

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameFNX-006
Drug Alias NameFNX-006
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase SRC inhibitorsRAF serine/threonine protein kinase inhibitorsVascular endothelial growth factor receptor 2 antagonists +[4] 
TargetsTyrosine-protein kinase SRCRAF serine/threonine protein kinaseVascular endothelial growth factor receptor 2 +[4] 
Therapy Area/IndicationsTriple Negative Breast NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSichuan UniversityChengdu Fannuoxi Biomedical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSichuan UniversityChengdu Fannuoxi Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast NeoplasmsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A